We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Thermo Fisher Scientific (TMO - Free Report) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?
Thermo Fisher Scientific's Business In-Depth
With that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In November 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb. 3, 2014, Thermo Fisher acquired Life Technologies Corporation.
In terms of end market served, there are four divisions-- pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics.
Following the acquisition, the new reporting segments are:
The Life Sciences Solutions segment, representing 23.3% of total revenues in 2025, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2025, this business registered growth of 7.7% from the 2024 level.
In September 2025, the company completed the acquisition of Solventum’s Purification & Filtration business. In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.
The Analytical Instruments segment, which represented 17% of total revenues in 2025, has been renamed to reflect the transfer of the bioprocess production business to the newly formed Life Sciences Solutions Segment. In 2025, this business registered growth of 1.2% from the 2024 level.
The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2025, this business registered growth of 3.6% from the 2024 level.
Laboratory Products and Biopharma Services, represents 55.8% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2025, this business registered growth of 3.6% from the 2024 level.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Thermo Fisher Scientific, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in October 2016 would be worth $4,590.93, or a gain of 359.09%, as of October 16, 2026, and this return excludes dividends but includes price increases.
The S&P 500 rose 263.06% and the price of gold increased 220.64% over the same time frame in comparison.
Analysts are forecasting more upside for TMO too.
Thermo Fisher is gaining from improving customer activity across all end markets, continued share gains and disciplined execution of its growth strategy. Pharma and biotech demand is advancing, led by bioproduction, clinical research and the research and safety channel. Clario and the filtration and separation business are bolstering the company's capabilities and supporting revenue synergies. New products, AI-enabled workflows and expanded customer collaboration centers reinforce its competitive position. Management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results. The Zacks Consensus Estimate projects 2026 EPS of $25.12 on revenues of $47.80 billion. Still, macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition remain key risks.
Over the past four weeks, shares have rallied 5.80%, and there have been 2 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in Thermo Fisher Scientific (TMO - Free Report) ten years ago? It may not have been easy to hold on to TMO for all that time, but if you did, how much would your investment be worth today?
Thermo Fisher Scientific's Business In-Depth
With that in mind, let's take a look at Thermo Fisher Scientific's main business drivers.
Headquartered in Waltham, MA, Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In November 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb. 3, 2014, Thermo Fisher acquired Life Technologies Corporation.
In terms of end market served, there are four divisions-- pharmaceutical and biotech, academic and government, industrial and applied, and healthcare and diagnostics.
Following the acquisition, the new reporting segments are:
The Life Sciences Solutions segment, representing 23.3% of total revenues in 2025, was added post the acquisition of Life Technologies. It incorporates the majority of the former Life Technologies and Thermo Fisher’s Biosciences businesses. In 2025, this business registered growth of 7.7% from the 2024 level.
In September 2025, the company completed the acquisition of Solventum’s Purification & Filtration business. In July 2024, Thermo Fisher acquired Olink, a provider of next-generation proteomics solutions.
The Analytical Instruments segment, which represented 17% of total revenues in 2025, has been renamed to reflect the transfer of the bioprocess production business to the newly formed Life Sciences Solutions Segment. In 2025, this business registered growth of 1.2% from the 2024 level.
The Specialty Diagnostics (SD) segment represents 10.5% of total revenues, formed after the acquisition of Phadia, serves customers in healthcare and clinical laboratories with a portfolio of diagnostic test kits, reagents and instruments used to increase the speed and accuracy of diagnoses to improve patient care. In 2025, this business registered growth of 3.6% from the 2024 level.
Laboratory Products and Biopharma Services, represents 55.8% of total revenues. It has been renamed to reflect the inclusion of the PPD acquisition. PPD has been referred to as a clinical research business within this segment. In 2025, this business registered growth of 3.6% from the 2024 level.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Thermo Fisher Scientific, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in October 2016 would be worth $4,590.93, or a gain of 359.09%, as of October 16, 2026, and this return excludes dividends but includes price increases.
The S&P 500 rose 263.06% and the price of gold increased 220.64% over the same time frame in comparison.
Analysts are forecasting more upside for TMO too.
Thermo Fisher is gaining from improving customer activity across all end markets, continued share gains and disciplined execution of its growth strategy. Pharma and biotech demand is advancing, led by bioproduction, clinical research and the research and safety channel. Clario and the filtration and separation business are bolstering the company's capabilities and supporting revenue synergies. New products, AI-enabled workflows and expanded customer collaboration centers reinforce its competitive position. Management raised its 2026 revenue and adjusted EPS outlook after better-than-expected second-quarter results. The Zacks Consensus Estimate projects 2026 EPS of $25.12 on revenues of $47.80 billion. Still, macroeconomic uncertainty, currency volatility, acquisition-related leverage and intense competition remain key risks.
Over the past four weeks, shares have rallied 5.80%, and there have been 2 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.